Over the last three decades, drug prices in India have declined from one of the highest to one of the lowest in the world. Yet, under the current healthcare model, only around 35 per cent of people in India have access to medicines. In the lead up to 2005, when TRIPS compliant regime was introduced in India, there were apprehensions about the drug prices rising under the new regime, which would further restrict access to medicine. This book examines the impact of TRIPS on drug prices and exports of drugs and pharmaceuticals in India. It goes on to develop a new healthcare model, which if implemented, would extend access to medicines to India's entire population. Sensitivity tests show that the proposed model is affordable, equitable and implementable, and can be replicated in other developing countries. This book is indispensable reading for all interested in development economics, intellectual property rights in developing countries, pharmaceutical markets and health systems.